Droxicam
Grundinformationen
- CAS
90101-16-9- Standard-SMILES
CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O- InChIKey
OEHFRZLKGRKFAS-UHFFFAOYSA-N- Summenformel
- C16H11N3O5S
- Durchschnittliche Molmasse
- 357,3 g/mol
- Monoisotopische Masse
- 357,04194163
Namen und Bezeichner
- Bevorzugter Name
- Droxicam
- IUPAC
- 5-methyl-6,6-dioxo-3-pyridin-2-yl-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4-dione
- Englischer Name
- Droxicam
- Summenformel
- C16H11N3O5S
- Molmasse
- 357.34
Namen und Synonyme
Droxicam90101-16-9DroxicamumF24ADO1E2DDTXSID70238035CHEBI:76133RefChem:1358475-methyl-3-(2-pyridyl)-2H,5H-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3H)dione-6,6-dioxideDTXCID90160526M01AC048-methyl-5-(pyridin-2-yl)-3-oxa-9??-thia-5,8-diazatricyclo(8.4.0.02,?)tetradeca-1(14),2(7),10,12-tetraene-4,6,9,9-tetrone5-Methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 6,6-dioxide
Weitere Namen anzeigen
E-318DroxarDobenamDroxicam USP/EP/BP5-Methyl-3-(2-pyridyl)-2H,5H-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide
Droxicam [INN]C16H11N3O5SE-3128MFCD008660325-methyl-6,6-dioxo-3-pyridin-2-yl-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4-dioneOmbolanDroxicam (INN)5-Methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino-[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 6,6-dioxide
Datenbank-Bezeichner
- CAS
90101-16-9
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 1,2
- Polarare Oberfläche (TPSA)
- 105 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 7
- Frei drehbare Bindungen
- 1
- Schwere Atome
- 25
- Formalladung
- 0
- Komplexität
- 741
Physikochemische Eigenschaften
- Schmelzpunkt
- 259 · 259-261°
- Siedepunkt
- 554.7 · 554.7±60.0 °C(Predicted)
- Dichte
- 1.68 · 1.68±0.1 g/cm3(Predicted)
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly, Heated)
- pka
- 3.8 · 3.80±0.19(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Off-White to Pale Yellow
- CAS Datenbank
- 90101 · 90101-16-9
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Droxicam
vMost-DILI-concern
8
Withdrawn
DOI:10.1016/j.drudis.2016.02.015
Sicherheitsdaten
- Toxizität
- LD50 orally in male, female mice, and male, female rats: 6192, 8841, 1434, 1994 mg/kg (Soler, 1986)
Chemie und Industrie
Pharmakologische Informationen
ATC Code
M - Musculo-skeletal system；M01 - Antiinflammatory and antirheumatic products；M01A - Antiinflammatory and antirheumatic products, non-steroids；M01AC - Oxicams；M01AC04 - Droxicam
QM - Musculo-skeletal system；QM01 - Antiinflammatory and antirheumatic products；QM01A - Antiinflammatory and antirheumatic products, non-steroids；QM01AC - Oxicams；QM01AC04 - Droxicam
Protein BindingData not available for prodrug. See [DB00554] for information on the active compound.
PharmacodynamicsDroxicam is a prodrug of [DB00554]. Droxicam administration produces anti-inflammatory, antirheumatic, analgesic, and antipyretic effects similar to [DB00554].
Mechanism of ActionDroxicam is converted to [DB00554] via hydrolysis of the ester group in the intestine. Droxicam administration inhibits the synthesis of prostaglandins by cyclooxygenase enzymes.
Biological Half-LifeData not available for prodrug. See [DB00554] for information on the active compound.
Metabolism/MetabolitesConverted to [DB00554] via ester hydrolysis.
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Absorption, Distribution and Excretion
Tmax of 7 h. Bioavailability equivalent to [DB00554] which is thought to be completely absorbed in humans based on data from rabbits.
Zugehörige Reaktionen
2
Notizen zur Verbindung
Wird geladen…